A securities class action lawsuit has been filed against Regenxbio Inc., alleging the company and certain officers and directors engaged in securities fraud or other unlawful business practices. The litigation follows the FDA placing clinical holds on Regenxbio’s investigational gene therapies RGX-111 and RGX-121 after a reported case of neoplasm in a trial participant, news that sent the company’s shares down about 18% on Jan. 28, 2026. Investors who purchased Regenxbio securities during the class period have until April 14, 2026 to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241646PRIMZONEFULLFEED9660598) on February 24, 2026, and is solely responsible for the information contained therein.